Genmab’s U.S.-listed ADS are trading higher as the market refocuses on shareholder-return actions disclosed around its March 19, 2026 Annual General Meeting (AGM), where shareholders approved the 2025 annual report and backed a reduction in share capital through the cancellation of treasury shares. The combination of formal capital reduction approval and recent repurchase activity can be interpreted as supportive for per-share metrics and capital efficiency, helping lift sentiment in a session without a fresh clinical-data headline.

At the AGM, shareholders approved reducing Genmab’s share capital via the cancellation of treasury shares, alongside standard annual meeting items including approval of the company’s 2025 results and granting discharge to the board and executive management. Separately, Genmab recently completed a share buyback program (completed March 13, 2026), which the company had initiated in February with a capped amount and purpose tied to equity compensation commitments—activity that can tighten supply and underscore management confidence.

Investors will likely watch for the timing mechanics of the treasury-share cancellation (and any related registry or exchange updates), plus whether Genmab signals additional repurchases beyond compensation-related needs. Beyond capital actions, attention may shift back to the company’s broader pipeline and strategic execution, where incremental updates—rather than one-off corporate governance headlines—typically drive more durable moves in biotech valuations.